Navigation Links
Amgen’s Second Quarter 2011 Revenue Increased 4 Percent to $4.0 Billion
Date:7/29/2011

Diluted (p)

$   1.25$
.37

(a)$   1.25$
.38

(a)Average shares used in calculationof earnings per share:Basic

927927959959Diluted (p)

935934

(a)964964

(a)(a) - (p)

See explanatory notes on the following pages.Amgen Inc.Condensed Consolidated Statements of Income andReconciliation of GAAP Earnings to "Adjusted" Earnings(In millions, except per share data)(Unaudited)Six months ended Six months ended June 30, 2011June 30, 2010GAAPAdjustments

"Adjusted"GAAPAdjustments

"Adjusted"Revenues:Product sales

$ 7,511$
-$
7,511$ 7,141$
-$
7,141Other revenues

154-154255-255Total revenues

7,665-7,6657,396-7,396Operating expenses:Cost of sales (excludes amortization of certainacquired intangible assets presented below)

1,166(6)

(a)1,1091,061(8)

(a)1,053(21)

(b)(23)

(c)(7)

(d)Research and development

1,555(19)

(a)1,5111,321(28)

(a)1,259(18)

(e)(34)

(e)(7)

(l)Selling, general and administrative

2,153(23)

(a)2,1221,870(29)

(a)1,841(8)

(f)Amortization of certain acquired intangible assets

147(147)

(g)-147(147)

(g)-Other

19(5)

(h)-(1)1

(h)-(3)

(i)(11)

(j)Total operating expenses

5,040(298)4,7424,398(245)4,153Operating income

2,6252982,9232,9982453,243Interest expense, net

257(76)

(k)181292(131)

(k)161Interest and other income, net

277-277178-178Income before income taxes

2,6453743,0192,8843763,260Provision for income taxes

350125

(m)480515137

(m)6525

(n)Net income

$ 2,295$ 244$
2,539$ 2,369$ 239$
2,608Earnings per share:Basic

$   2.47$
2.73$   2.44$
2.69Diluted (p)

$   2.45$
2.71

(a)$  
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine technology :

1. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
2. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
3. Amgen’s First Quarter 2011 Revenue Increased 3 Percent to $3.7 Billion
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
8. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
(Date:10/2/2014)... The Business Intelligence Group today announced ... Business program. The BIG Awards specialize in recognizing ... process scored by well-known and experienced leaders and ... this year epitomize what is going right with ... Business Intelligence Group. “The sheer amount of innovation ...
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Amy Norton HealthDay Reporter ... who have trouble smelling the roses -- literally -- may face ... research suggests. In a study of over 3,000 older Americans, ... rose, orange and peppermint were more than three times as likely ... sharp sense of smell. In fact, anosmia -- the inability ...
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... Online ... clip on teen self esteem as part of its ongoing campaign and mission to affect change ... ... to the number one issue affecting today’s teen girl – low self esteem. It is a ...
... ... Championships Played on SnapSports® Volleyball Surfaces for a second year in a row. ... Pheonix, AZ (PRWEB) ... this year,s Phoenix Volleyball Festival on SnapSports® BounceBack® volleyball surfaces. The tournament is one ...
... ... and Organic Meat Raised Locally, , ... Seattle, WA (PRWEB) July 2, 2010 -- Bill the Butcher Inc. ... said J’Amy Owens, chief executive officer., , ,Located at 3800 34th Ave West in ...
... Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a ... (CLL), regardless of the patient,s underlying genetic abnormalities, according ... in Blood , the journal of the American ... were diagnosed in the United States in 2009 and ...
... the brains of humans and other mammals differed from the ... presumably better). This belief was based, in part, upon the ... the brain responsible for complex cognitive behaviors. A new ... Diego School of Medicine finds that a comparable region in ...
... ... newly expanded pain treatment center in in the Los Angeles area. , ... (PRWEB) July 2, 2010 -- API and the ... Arcadia, California 91007. The Los Angeles area pain management clinic supplements the existing Encino Surgical ...
Cached Medicine News:Health News:Bellaboo Releases One Girl At A Time Documentary 2Health News:Phoenix Volleyball Festival Championships Played on SnapSports Volleyball Surfaces 2Health News:In Time for July 4th Grilling, Bill the Butcher Opens 5th Butcher Shop 2Health News:Patients with treatment-resistant CLL respond positively to stem cell transplants 2Health News:Our brains are more like birds' than we thought 2Health News:Our brains are more like birds' than we thought 3Health News:Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center 2
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
... Afinion HbA1c test and the ... you reliable facts conveniently available ... them. Advising the patient can ... The HbA1c Test Cartridge contains ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: